Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: Role of M1 muscarinic receptors

Marta Maltese, Giuseppina Martella, Graziella Madeo, Irene Fagiolo, Annalisa Tassone, Giulia Ponterio, Giuseppe Sciamanna, Pierre Burbaud, P. Jeffrey Conn, Paola Bonsi, Antonio Pisani

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Broad-spectrum muscarinic receptor antagonists have represented the first available treatment for different movement disorders such as dystonia. However, the specificity of these drugs and their mechanism of action is not entirely clear. We performed a systematic analysis of the effects of anticholinergic drugs on short- and long-term plasticity recorded from striatal medium spiny neurons from DYT1 dystonia knock-in (Tor1a+/Δgag) mice heterozygous for ΔE-torsinA and their controls (Tor1a+/+ mice). Antagonists were chosen that had previously been proposed to be selective for muscarinic receptor subtypes and included pirenzepine, trihexyphenydil, biperiden, orphenadrine, and a novel selective M1 antagonist, VU0255035. Tor1a+/Δgag mice exhibited a significant impairment of corticostriatal synaptic plasticity. Anticholinergics had no significant effects on intrinsic membrane properties and on short-term plasticity of striatal neurons. However, they exhibited a differential ability to restore the corticostriatal plasticity deficits. A complete rescue of both long-term depression (LTD) and synaptic depotentiation (SD) was obtained by applying the M1-preferring antagonists pirenzepine and trihexyphenidyl as well as VU0255035. Conversely, the nonselective antagonist orphenadrine produced only a partial rescue of synaptic plasticity, whereas biperiden and ethopropazine failed to restore plasticity. The selectivity for M1 receptors was further demonstrated by their ability to counteract the M1-dependent potentiation of N-methyl-d-aspartate (NMDA) current recorded from striatal neurons. Our study demonstrates that selective M1 muscarinic receptor antagonism offsets synaptic plasticity deficits in the striatum of mice with the DYT1 dystonia mutation, providing a potential mechanistic rationale for the development of improved antimuscarinic therapies for this movement disorder.

Original languageEnglish
Pages (from-to)1655-1665
Number of pages11
JournalMovement Disorders
Volume29
Issue number13
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Drug Repositioning
Muscarinic M1 Receptors
Neuronal Plasticity
Dystonia
Cholinergic Antagonists
Corpus Striatum
Orphenadrine
Biperiden
Long-Term Synaptic Depression
Pirenzepine
Muscarinic Antagonists
Movement Disorders
Muscarinic Receptors
Neurons
Trihexyphenidyl
Aspartic Acid
Pharmaceutical Preparations
Mutation
Membranes

Keywords

  • Dystonia
  • Muscarinic receptor antagonists
  • Striatum
  • Synaptic plasticity

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia : Role of M1 muscarinic receptors. / Maltese, Marta; Martella, Giuseppina; Madeo, Graziella; Fagiolo, Irene; Tassone, Annalisa; Ponterio, Giulia; Sciamanna, Giuseppe; Burbaud, Pierre; Conn, P. Jeffrey; Bonsi, Paola; Pisani, Antonio.

In: Movement Disorders, Vol. 29, No. 13, 01.11.2014, p. 1655-1665.

Research output: Contribution to journalArticle

Maltese, M, Martella, G, Madeo, G, Fagiolo, I, Tassone, A, Ponterio, G, Sciamanna, G, Burbaud, P, Conn, PJ, Bonsi, P & Pisani, A 2014, 'Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: Role of M1 muscarinic receptors', Movement Disorders, vol. 29, no. 13, pp. 1655-1665. https://doi.org/10.1002/mds.26009
Maltese M, Martella G, Madeo G, Fagiolo I, Tassone A, Ponterio G et al. Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: Role of M1 muscarinic receptors. Movement Disorders. 2014 Nov 1;29(13):1655-1665. https://doi.org/10.1002/mds.26009
Maltese, Marta ; Martella, Giuseppina ; Madeo, Graziella ; Fagiolo, Irene ; Tassone, Annalisa ; Ponterio, Giulia ; Sciamanna, Giuseppe ; Burbaud, Pierre ; Conn, P. Jeffrey ; Bonsi, Paola ; Pisani, Antonio. / Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia : Role of M1 muscarinic receptors. In: Movement Disorders. 2014 ; Vol. 29, No. 13. pp. 1655-1665.
@article{bd024e55629a4cff8e5047ab485554b2,
title = "Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: Role of M1 muscarinic receptors",
abstract = "Broad-spectrum muscarinic receptor antagonists have represented the first available treatment for different movement disorders such as dystonia. However, the specificity of these drugs and their mechanism of action is not entirely clear. We performed a systematic analysis of the effects of anticholinergic drugs on short- and long-term plasticity recorded from striatal medium spiny neurons from DYT1 dystonia knock-in (Tor1a+/Δgag) mice heterozygous for ΔE-torsinA and their controls (Tor1a+/+ mice). Antagonists were chosen that had previously been proposed to be selective for muscarinic receptor subtypes and included pirenzepine, trihexyphenydil, biperiden, orphenadrine, and a novel selective M1 antagonist, VU0255035. Tor1a+/Δgag mice exhibited a significant impairment of corticostriatal synaptic plasticity. Anticholinergics had no significant effects on intrinsic membrane properties and on short-term plasticity of striatal neurons. However, they exhibited a differential ability to restore the corticostriatal plasticity deficits. A complete rescue of both long-term depression (LTD) and synaptic depotentiation (SD) was obtained by applying the M1-preferring antagonists pirenzepine and trihexyphenidyl as well as VU0255035. Conversely, the nonselective antagonist orphenadrine produced only a partial rescue of synaptic plasticity, whereas biperiden and ethopropazine failed to restore plasticity. The selectivity for M1 receptors was further demonstrated by their ability to counteract the M1-dependent potentiation of N-methyl-d-aspartate (NMDA) current recorded from striatal neurons. Our study demonstrates that selective M1 muscarinic receptor antagonism offsets synaptic plasticity deficits in the striatum of mice with the DYT1 dystonia mutation, providing a potential mechanistic rationale for the development of improved antimuscarinic therapies for this movement disorder.",
keywords = "Dystonia, Muscarinic receptor antagonists, Striatum, Synaptic plasticity",
author = "Marta Maltese and Giuseppina Martella and Graziella Madeo and Irene Fagiolo and Annalisa Tassone and Giulia Ponterio and Giuseppe Sciamanna and Pierre Burbaud and Conn, {P. Jeffrey} and Paola Bonsi and Antonio Pisani",
year = "2014",
month = "11",
day = "1",
doi = "10.1002/mds.26009",
language = "English",
volume = "29",
pages = "1655--1665",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "13",

}

TY - JOUR

T1 - Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia

T2 - Role of M1 muscarinic receptors

AU - Maltese, Marta

AU - Martella, Giuseppina

AU - Madeo, Graziella

AU - Fagiolo, Irene

AU - Tassone, Annalisa

AU - Ponterio, Giulia

AU - Sciamanna, Giuseppe

AU - Burbaud, Pierre

AU - Conn, P. Jeffrey

AU - Bonsi, Paola

AU - Pisani, Antonio

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Broad-spectrum muscarinic receptor antagonists have represented the first available treatment for different movement disorders such as dystonia. However, the specificity of these drugs and their mechanism of action is not entirely clear. We performed a systematic analysis of the effects of anticholinergic drugs on short- and long-term plasticity recorded from striatal medium spiny neurons from DYT1 dystonia knock-in (Tor1a+/Δgag) mice heterozygous for ΔE-torsinA and their controls (Tor1a+/+ mice). Antagonists were chosen that had previously been proposed to be selective for muscarinic receptor subtypes and included pirenzepine, trihexyphenydil, biperiden, orphenadrine, and a novel selective M1 antagonist, VU0255035. Tor1a+/Δgag mice exhibited a significant impairment of corticostriatal synaptic plasticity. Anticholinergics had no significant effects on intrinsic membrane properties and on short-term plasticity of striatal neurons. However, they exhibited a differential ability to restore the corticostriatal plasticity deficits. A complete rescue of both long-term depression (LTD) and synaptic depotentiation (SD) was obtained by applying the M1-preferring antagonists pirenzepine and trihexyphenidyl as well as VU0255035. Conversely, the nonselective antagonist orphenadrine produced only a partial rescue of synaptic plasticity, whereas biperiden and ethopropazine failed to restore plasticity. The selectivity for M1 receptors was further demonstrated by their ability to counteract the M1-dependent potentiation of N-methyl-d-aspartate (NMDA) current recorded from striatal neurons. Our study demonstrates that selective M1 muscarinic receptor antagonism offsets synaptic plasticity deficits in the striatum of mice with the DYT1 dystonia mutation, providing a potential mechanistic rationale for the development of improved antimuscarinic therapies for this movement disorder.

AB - Broad-spectrum muscarinic receptor antagonists have represented the first available treatment for different movement disorders such as dystonia. However, the specificity of these drugs and their mechanism of action is not entirely clear. We performed a systematic analysis of the effects of anticholinergic drugs on short- and long-term plasticity recorded from striatal medium spiny neurons from DYT1 dystonia knock-in (Tor1a+/Δgag) mice heterozygous for ΔE-torsinA and their controls (Tor1a+/+ mice). Antagonists were chosen that had previously been proposed to be selective for muscarinic receptor subtypes and included pirenzepine, trihexyphenydil, biperiden, orphenadrine, and a novel selective M1 antagonist, VU0255035. Tor1a+/Δgag mice exhibited a significant impairment of corticostriatal synaptic plasticity. Anticholinergics had no significant effects on intrinsic membrane properties and on short-term plasticity of striatal neurons. However, they exhibited a differential ability to restore the corticostriatal plasticity deficits. A complete rescue of both long-term depression (LTD) and synaptic depotentiation (SD) was obtained by applying the M1-preferring antagonists pirenzepine and trihexyphenidyl as well as VU0255035. Conversely, the nonselective antagonist orphenadrine produced only a partial rescue of synaptic plasticity, whereas biperiden and ethopropazine failed to restore plasticity. The selectivity for M1 receptors was further demonstrated by their ability to counteract the M1-dependent potentiation of N-methyl-d-aspartate (NMDA) current recorded from striatal neurons. Our study demonstrates that selective M1 muscarinic receptor antagonism offsets synaptic plasticity deficits in the striatum of mice with the DYT1 dystonia mutation, providing a potential mechanistic rationale for the development of improved antimuscarinic therapies for this movement disorder.

KW - Dystonia

KW - Muscarinic receptor antagonists

KW - Striatum

KW - Synaptic plasticity

UR - http://www.scopus.com/inward/record.url?scp=84911196137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911196137&partnerID=8YFLogxK

U2 - 10.1002/mds.26009

DO - 10.1002/mds.26009

M3 - Article

C2 - 25195914

AN - SCOPUS:84911196137

VL - 29

SP - 1655

EP - 1665

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 13

ER -